The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives-Reference-Cited by-同舟云学术

The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives

Published:2022 Issue: Volume: Page:109-122
ISSN:
Container-title:Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
language:
Short-container-title:

Author:

Basile Giuseppe,Cacciamani Giovanni Enrico,Scuderi Simone,Barletta Francesco,Cucchiara Vito,Mazzone Elio

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-80546-3_9

Reference52 articles.

1. Witjes JA, et al., European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol, 2020;79(1). https://doi.org/10.1016/j.eururo.2020.03.055. Elsevier B.V.

2. Babjuk M, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol. 2019;76(5):639–57. https://doi.org/10.1016/j.eururo.2019.08.016. Elsevier B.V.

3. Stein JP, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75. https://doi.org/10.1200/JCO.2001.19.3.666.

4. Vetterlein MW, et al. Improving estimates of perioperative morbidity after radical cystectomy using the European Association of Urology Quality Criteria for standardized reporting and introducing the comprehensive complication index [formula presented]. Eur Urol. 2020;77(1):55–65. https://doi.org/10.1016/j.eururo.2019.08.011.

5. Mottet N, et al. Management of bladder cancer in older patients: position paper of a SIOG Task Force. J Geriatr Oncol. 2020;11:1043–53. https://doi.org/10.1016/j.jgo.2020.02.001.